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Background: The broth microdilution (BMD) method is currently the recommended technique to determine
susceptibility to colistin.
Objectives: We evaluated the accuracy of three commercialized BMD panels [Sensititre (ThermoFisher
Diagnostics), UMIC (Biocentric) andMicroScan (Beckman Coulter)] to determine colistin susceptibility.
Methods: A collection of 185 isolates of Gram-negative bacilli (133 colistin resistant and 52 colistin susceptible)
was tested. Manual BMD according to EUCAST guidelines was used as the reference method, and EUCAST 2017
breakpoints were used for susceptibility categorization.
Results: The UMIC system gave the highest rate of very major errors (11.3%) compared with the Sensititre and
MicroScan systems (3% and 0.8%, respectively). A high rate of major errors (26.9%) was found with the
MicroScan system due to an overestimation of the MICs for the non-fermenting Gram-negative bacilli, whereas
nomajor errors were foundwith the Sensititre and UMIC systems.
Conclusions: The UMIC system was easy to use, but failed to detect .10% of colistin-resistant isolates. The
MicroScan system showed excellent results for enterobacterial isolates, but non-susceptible results for non-
fermenters should be conﬁrmed by another method and the range of MICs tested was narrow. The Sensititre
systemwas themost reliablemarketed BMD panel with a categorical agreement of 97.8%.
Introduction
Occurrence of MDR Gram-negative bacilli is a growing concern and
has led to a renewed interest in the use of polymyxins (colistin, poly-
myxin B) as last-resort antibiotics.1 However, colistin susceptibility
testing is currently challenging, with the disc-diffusion method and
the Etest systems giving high rates of false-susceptibility results (up
to 30%).2 Since March 2016, the joint CLSI–EUCAST Polymyxin
BreakpointsWorking Group has recommended the brothmicrodilu-
tion (BMD)method as the referencemethod to determine suscepti-
bility to colistin (www.eucast.org).3 However, this method is often
not implementable in routine practice due to a laborious manual
preparation. Marketed BMD panels such as Sensititre (ThermoFisher
Diagnostics, Dardilly, France), UMIC (Biocentric, Bandol, France) and
MicroScan (Beckman Coulter, Villepinte, France) systems may be
considered as interesting alternatives, but the performances of
these systems for detecting colistin resistance have not been care-
fully evaluated.
To date, only two studies have investigated the performance of
the MicroScan system for colistin susceptibility testing. One study
included Acinetobacter spp. isolates only and showed a categorical
agreement (CA) of 87.3%,4 while the second included Klebsiella
pneumoniae isolates only and showed a susceptibility of 88.1%.5 A
single study has evaluated the Sensititre method, and a 96% CA
with the reference BMDmethod was found, with no false-suscepti-
bility results reported.6 The performance of the UMIC system for
determining colistin susceptibility has never beenassessed.
The objective of this study was therefore to evaluate and com-
pare the performances of the Sensititre system, the UMIC system
and the MicroScan system for determining colistin susceptibility
using a collection of 185 isolates of Gram-negative bacilli.
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Published in "Journal of Antimicrobial Chemotherapy doi: 10.1093/jac/dky012, "
which should be cited to refer to this work.
Materials and methods
Bacterial isolates
A collection of 185 Gram-negative isolateswas tested. Fifty-two isolateswere
susceptible to colistin, 19 isolates belonged to a genus naturally resistant to
colistin (Proteus, Providencia,Morganella, Serratia andHafnia) and 114 isolates
belonged to various species (Klebsiella spp., Escherichia coli, Enterobacter spp.,
Salmonella enterica, Pseudomonas aeruginosa, Stenotrophomonas malto-
philiaandAcinetobacter baumannii) andpresentedacquired resistance tocoli-
stin. The colistin-resistant isolates were collected worldwide from clinical
samples. Identiﬁcation was performed using theMicroﬂex bench-top MALDI-
TOF mass spectrometer (Bruker, Champs-sur-Marne, France). None of the
strainswas clonally related.
Molecular genotyping for colistin resistance
Colistin-resistant isolates were screened for the plasmid-mediated colistin
resistance genesmcr-1,mcr-2,mcr-3 andmcr-4 as described previously.7–11
Chromosomally encoded mutations in genes potentially involved in colistin
resistance (pmrA, pmrB, phoP, phoQ, mgrB and crrB genes) were also
searched for as described previously.12–18
Colistin susceptibility testing
Preparation of the BMD panels
The features of the various commercialized panels used in this study are
summarized in Table 1. Each isolate was tested with the four techniques
in the same experiment and from the same starting bacterial suspension
with a turbidity equivalent to that of a 0.5 McFarland standard. The panels
were prepared as recommended by each manufacturer. The BMD
referencemethodwas performed according to the EUCAST guidelines (www.
eucast.org) in 96-well non-treated polystyrenemicroplates (ref. 82.1582.001;
Sarstedt, Nu¨mbrecht, Germany). Dilutions of colistin sulfate (ref. C4461;
Sigma–Aldrich, St Louis, MO, USA) ranging from 0.12 to 128mg/L weremade
extemporaneously in CAMHB (ref. YT3462; ThermoFisher Diagnostics), with-
out addition of polysorbate 80 (Tween 80), and a ﬁnal concentration of
5%105cfu/mL of bacteria was added to each well. All the BMD panels were
read visually after 18–20h of incubation at 35+2C. The colistin-susceptible
ATCC 25922 E. coli and ATCC 27853 P. aeruginosa strains were included in all
the experiments as quality controls.
Analysis of the results
It should be noted that all inspections were visual and not automated.
Categorization of the isolates was performed on the basis of the EUCAST
susceptible and resistant breakpoints (2 and .2mg/L, respectively). For
S. maltophilia isolates, the same breakpoint of 2mg/L was arbitrarily
chosen, given the lack of EUCAST breakpoints.
Results obtained with the three commercialized BMD panels were com-
pared with those obtained with the BMD reference method. Discrepancies
were determined for each method in order to assess how accurately they
determined susceptibility to colistin. Isolates forwhich discrepant susceptibil-
ity results were observed were retested twice with the four methods.
Unsolved discrepancies were then maintained in the database for perform-
ance evaluation. Errors were ranked as follows: very major errors (VMEs), for
isolates categorized as susceptible using the marketed panel, but resistant
by the BMD reference method (false-susceptibility result); and major errors
(MEs), for isolates categorized as resistant using themarketed panel, but sus-
ceptible by the BMD referencemethod (false-resistant result). The number of
resistant and susceptible isolates were used as denominators for VME and
ME calculations, respectively. CA was deﬁned as the percentage of isolates
classiﬁed into the same category by the commercialized panel compared
with the BMD referencemethod. Acceptance criteria that provide the require-
ments and speciﬁcations toevaluateperformancesof antimicrobial suscepti-
bility test devices were those deﬁned by the ISO standards (VMEs and MEs
must be3%andCAmust be90%).19
Results
The 133 colistin-resistant Gram-negative isolates analysed in this
study presented various levels of resistance (MICs ranging from
4 to.128mg/L by using the BMD referencemethod) (Table 2).
The tested isolates exhibited various genotypes conferring coli-
stin resistance, i.e. related to various chromosomal mutations,
and/or acquisition of plasmid-mediated genes (Table 2). Thirty-
ﬁve K. pneumoniae isolates presentedmutations in pmrAB, phoPQ,
Table 1. Features of the BMD panels
Sensititre UMIC MicroScan
Manufacturer ThermoFisher Diagnostics Biocentric Beckman Coulter
Reference of the panel FRCOL (custom plate) UM-COL-040 NM44
Range of colistin concentrations
tested (mg/L)
0.12–128 0.06–64 2–4
Description of the panel 96-well microplate to test only colistina 12-well panel
to test only
colistin
96-well microplate:
2 wells to test colistin,
the others to test
additional antibioticsa
Number of strains tested by panel 8 1 1
Medium CAMHB with TES (ref. YT3462) CAMHB water with PLURONIC
Inoculation manual or semi-automated with the AIMTM
automated inoculation delivery system
manual semi-automated with the
RENOK inoculator system
Incubation time (h) 18–24 18–24 16–20
Reading visual, semi-automated with VizionV
R
or automated with OptireadV
R
visual visual, semi-automated with
autoSCAN-4 or automated
with the WalkAway plus system
aOther panels testing colistin are also available.
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Table 2. MIC results obtained with the four BMDmethods
Species (number of isolates) Genotype
Colistin MIC (mg/L)
reference BMD Sensititre UMIC MicroScan
Isolates naturally resistant to colistin
Proteus mirabilis (n"1),
Proteus vulgaris (n"1),
Providencia stuartii (n"1),
Morgenalla morganii (n"1),
Serratia marcescens (n"1)
NA .128 .128 .64 .4
H. alvei (n"2) NA 8 4–8 2 4 to .4
H. alvei (n"1) NA 8 8 4–8 .4
H. alvei NA 16 16 16 .4
Hafnia paralvei NA 4 4 4 4
H. paralvei (n"9) NA 8 4–8 4–8 .4
Isolates with acquired colistin resistance
K. pneumoniae plasmid-mediatedmcr-1 gene 8 4 2 .4
K. pneumoniae PmrA G53C 32 16 32 .4
K. pneumoniae PmrA G53S 16 16 16 .4
K. pneumoniae PmrA G53S 32 16 16 .4
K. pneumoniae PmrB T157P 8 8 8 .4
K. pneumoniae PmrB T157P 16 8 16 .4
K. pneumoniae PhoP D191Y 64 32 64 .4
K. pneumoniae PhoQ R16C 128 64 64 .4
K. pneumoniae MgrB C28 (MgrB truncated) 128 64 64 .4
K. pneumoniae (n"2) MgrB Q30 (MgrB truncated) 64 32 64 .4
K. pneumoniae MgrB W47 (MgrB truncated) 32 16 16 .4
K. pneumoniae MgrB W20R 16 16 16 .4
K. pneumoniae MgrB M27K 16 16 32 .4
K. pneumoniae MgrB C39Y 4 4 8 .4
K. pneumoniae MgrB N42Y and K43I 4 4 8 .4
K. pneumoniae MgrB I45T 32 32 16 .4
K. pneumoniae MgrB P46S 16 8 32 .4
K. pneumoniae MgrB ISEcp1/blaCTX-M-15 32 16 32 .4
K. pneumoniae IS10R inmgrB promotor 64 64 64 .4
K. pneumoniae ISKpn14 inmgrB promotor 32 32 16 .4
K. pneumoniae IS102-like inmgrB gene 128 64 .64 .4
K. pneumoniae IS5-like inmgrB gene 32 16 32 .4
K. pneumoniae IS5-like inmgrB gene 32 16 64 .4
K. pneumoniae ISKpn13 inmgrB gene 64 32 .64 .4
K. pneumoniae ISKpn14 inmgrB gene 8 8 16 .4
K. pneumoniae IS903b-like inmgrB gene 64 32 64 .4
K. pneumoniae mgrB Dnt23 (frameshift) 8 8 8 .4
K. pneumoniae mgrB Dnt74 (frameshift) 32 32 64 .4
K. pneumoniae mgrB Dnt100 (frameshift) 32 16 32 .4
K. pneumoniae mgrB Dnt23/33 (frameshift) 128 64 .64 .4
K. pneumoniae (n"2) DmgrB 32 16 32 .4
K. pneumoniae CrrB N141Y 128 64 .64 .4
K. pneumoniae CrrB P151L .128 .128 .64 .4
K. pneumoniae CrrB G183V 32 32 .64 .4
K. pneumoniae — 4 4 8 .4
K. pneumoniae — 8 4 4 .4
K. pneumoniae — 16 16 16 .4
K. pneumoniae — 64 32 32 .4
K. pneumoniae — 128 64 .64 .4
Klebsiella oxytoca ISKpn26-like inmgrB promotor 32 16 32 .4
Continued
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Table 2. Continued
Species (number of isolates) Genotype
Colistin MIC (mg/L)
reference BMD Sensititre UMIC MicroScan
E. coli plasmid-mediatedmcr-1 gene 4 4 2 .4
E. coli plasmid-mediatedmcr-1 gene 8 4 2 .4
E. coli (n"13) plasmid-mediatedmcr-1 gene 8 4–8 4–8 .4
E. coli (n"2) plasmid-mediatedmcr-1 gene 16 8–16 8 .4
E. coli plasmid-mediatedmcr-1 gene 64 64 32 .4
E. coli plasmid-mediatedmcr-2 gene 4 4 2 .4
E. coli PmrA G15R 8 8 8 .4
E. coli PmrB R11L 4 4 2 .4
E. coli PmrB L13P 16 8 8 .4
E. coli PmrB G19E 4 4 4 4
E. coli PmrB G22E 8 8 4 .4
E. coli PmrB T114P 4 4 4 .4
E. coli PmrB R138H 8 4 8 .4
E. coli PmrB R138H, G305R 8 4 8 .4
E. coli PmrB D152V 8 8 4 .4
E. coli PmrB D315N 16 16 8 .4
E. coli PmrB T114P!plasmid-mediated
mcr-1 gene
16 16 16 .4
E. coli (n"4) — 8 4 4 .4
E. coli — 16 16 8 .4
E. cloacae — 4 2 4 4
E. cloacae — 8 8 16 .4
E. cloacae (n"2) — 16 8 16 .4
E. cloacae — 16 16 32 .4
E. cloacae — 64 32 .64 4
E. cloacae (n"2) — .128 .128 .64 .4
E. cloacae — .128 .128 .64 .4
E. aerogenes — 4 2 4 .4
E. aerogenes — 4 4 4 4
S. entericaa ArcA T111P, EnvZ Del13nt 4 2 2 4
S. entericaa pmrD gene ampliﬁcation, ArcA V9L,
MurD S161T
4 2 2 .4
S. enterica — 4 4 1 .4
S. enterica plasmid-mediatedmcr-4-like gene 4 4 2 .4
S. enterica — 4 4 4 .4
S. enterica plasmid-mediatedmcr-1 gene 16 8 8 .4
S. entericaa pmrD gene ampliﬁcation, ArcA L50Q,
MurD D418Y, FliM L54Q
64 32 32 .4
P. aeruginosa — 16 8 16 .4
P. aeruginosa — 64 16 .64 .4
P. aeruginosa — 128 64 .64 .4
S. maltophilia — 4 4 8 .4
S. maltophilia — 8 4 1 .4
S. maltophilia — 8 16 2 .4
S. maltophilia — 16 16 0.12 .4
S. maltophilia — 32 16 0.5 .4
S. maltophilia — 32 16 64 .4
S. maltophilia — 64 32 4 .4
S. maltophilia — 128 64 .64 .4
A. baumannii PmrA E8D, PmrB R263P 128 64 64 2
A. baumannii PmrA E54G, PmrB E140V .128 .128 .64 .4
Continued
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mgrB or crrB genes, and 11 E. coli and 6 A. baumannii isolates
exhibited mutations in pmrAB genes. Twenty-three enterobacte-
rial isolates recovered worldwide carried plasmid-mediated coli-
stin resistancemcr-1,mcr-2 ormcr-4-like genes.
Comparison of the UMIC system with the BMD
reference method
The UMIC system did not detect two colistin-resistant Hafnia alvei
isolates that presented lowMIC values of colistin (8mg/L). It failed
also to detect ﬁve isolates (three E. coli, a single K. pneumoniae
and a single Salmonella enterica) possessing plasmid-mediated
colistin resistance genes (mcr-1, mcr-2 or mcr-4-like) and exhibit-
ing a low level of resistance (MICs from4 to 8mg/L). Several enter-
obacterial isolates (a single E. coli and three S. enterica isolates)
also exhibiting low MICs of colistin (MIC of 4mg/L), but lacking the
plasmid-mediated mcr-1, mcr-2, mcr-3 and mcr-4 genes, were
also falsely detected as susceptible by the UMIC system. For all
these isolates, the UMIC system gave MICs of 1 or 2mg/L. Finally,
four S. maltophilia isolates with higher colistin MICs (ranging from
8 to 32mg/L) were not detected as resistant by the UMIC system,
which gave lower MICs ranging from 0.12 to 2mg/L. For one
S.maltophilia isolate, the CAwas correct, but the colistin MIC found
with the UMIC system was 4mg/L, while the MIC was actually
64mg/L bymanual BMD.
Comparison of the Sensititre system with the BMD
reference method
This comparison showedahigh rate of agreement. TheSensititre sys-
tem detected correctly the 19 isolates naturally resistant to colistin
and all the 23 enterobacterial isolates harbouring plasmid-mediated
colistin resistance. Except for a single P. aeruginosa isolate, the MICs
determined by the Sensititre system for all the resistant isolateswere
Table 2. Continued
Species (number of isolates) Genotype
Colistin MIC (mg/L)
reference BMD Sensititre UMIC MicroScan
A. baumannii PmrB I163S 32 32 32 .4
A. baumannii PmrB P170L 16 16 32 .4
A. baumannii PmrB G260D .128 .128 .64 .4
A. baumannii PmrB Q265P .128 .128 .64 .4
A. baumannii — 16 16 16 .4
A. baumannii — .128 .128 .64 .4
Colistin-susceptible isolates
K. pneumoniae (n"5) NA 0.12–0.25 0.5 0.25–0.5 2
K. pneumoniae NA 1 1 0.5 2
K. oxytoca NA 0.12 0.25–0.5 0.12–0.25 2
E. coli (n"5) NA 0.12 0.25–0.5 0.12–0.5 2
E. coli (n"6) NA 0.25 0.25–0.5 0.25–0.5 2
E. coli (n"2) NA 0.5 0.5 0.25–0.5 2
E. cloacae (n"4) NA 0.12 0.25–0.5 0.12–0.5 2
E. cloacae NA 0.25 0.5 0.25 4
E. cloacae NA 0.25 0.5 0.5 2
E. cloacae NA 0.5 0.5 0.5 2
E. aerogenes (n"2) NA 0.12 0.5 0.12–0.25 2
S. enterica NA 0.5 1 0.5 2
S. enterica NA 2 2 2 2
Citrobacter koseri NA 0.25 0.5 0.5 2
P. aeruginosa (n"2) NA 0.25 0.5 0.12–0.25 2
P. aeruginosa (n"8) NA 1 1–2 1 4
P. aeruginosa (n"2) NA 1 2 1 2
P. aeruginosa NA 2 2 1 2
S. maltophilia NA 0.5 0.5 0.5 2
S. maltophilia NA 1 1 1 .4
S. maltophilia NA 1 2 0.12 4
A. baumannii NA 0.5 1 2 4
A. baumannii (n"2) NA 1 1–2 0.5 4
A. baumannii NA 1 1 0.5 2
NA, not applicable.
The discordant results compared with the reference method are in bold.
aThese S. enterica strains were genotyped by Hjort et al.22
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equal or only differed by one dilution when compared with those
determined by the BMD reference method. However, two
Enterobacter spp. and two S. enterica isolates presenting low MICs
(4mg/L) were falsely detected as susceptible by the Sensititre sys-
tem,whichgaveMICs of 2mg/L.
Comparison of the MicroScan system with the BMD
reference method
The MicroScan system detected all the colistin-resistant isolates,
except a single A. baumannii isolate showing an MIC of colistin of
128mg/L, whereas the MicroScan system gave an MIC of 2mg/L.
However, 13 out of the 20 colistin-susceptible non-fermenters
(13 P. aeruginosa, 3 S. maltophilia and 4 A. baumannii) were found
resistant to colistin with the MicroScan system. Moreover, a single
Enterobacter cloacae isolate was also found falsely resistant with an
MICof 4mg/L.
Discussion
In this study, we evaluated threemarketed BMD panels (Sensititre,
UMIC and MicroScan) to determine MICs of colistin for a collection
of 185 isolates of Gram-negative bacilli.
The UMIC system is a novel BMD panel for colistin susceptibility
testing. Its advantages are the absence of any need for speciﬁc
equipment and the form of the panel allowing colistin susceptibil-
ity to be tested for a single strain. However, the UMIC system failed
to detect 15 isolates among the 133 colistin-resistant isolates, giv-
ing a high rate of VMEs (11.3%) (Table 3). It failed to detect colistin
resistance in two H. alvei isolates (Table 2). In fact, we recently
showed that the H. alvei species exhibits intrinsic resistance to coli-
stin, though the resistance was of low level (MICs ranging from 4
to16mg/L).20 UMIC failed also to detect nine other enterobacterial
isolates with low-level resistance to colistin (MICs ranging from 4
to 8mg/L), whereas the MICs of colistin reported with this system
were close to the breakpoints (MICs of 1 or 2mg/L, respectively)
(Table 2). Five of those isolates possessed a plasmid-mediated col-
istin resistance determinant (mcr-1,mcr-2 ormcr-4-like). This mis-
detection could underestimate the carriage of plasmid-mediated
colistin resistance isolates, and thus participate in the spread of
this resistance trait by delaying the rapid implementation of
adequate hygiene measures. For those enterobacterial isolates
with MICs of 1 or 2mg/L, a more sensitive method should be used
for conﬁrmation, such as the BMD reference method or the newly
developed rapid test (Rapid PolymyxinNP test).21 TheUMIC system
also widely underestimated the MICs for isolates belonging to the
S. maltophilia species, and failed to detect high-level resistance
(MICs from8 to32mg/L).
The performance of the Sensititre system was much better, but
this system failed to detect four colistin-resistant isolates (one
E. cloacae isolate, one Enterobacter aerogenes isolate and two
S. enterica isolates) (Table 2), giving an acceptable VME rate of 3%
(Table 3). The two tested Salmonella isolates not detected as colistin
resistant were characterized as heteroresistant by Hjort et al.22 This
lack of detection could therefore be due to the presence of colistin-
resistant subpopulations. Gue´rin et al.23 also showed that some
subpopulations of E. cloacae isolates may exhibit heteroresistance to
colistin, which could explain a misdetection of that resistance for one
of the isolates in our study. Of the 133 colistin-resistant isolates, the
Sensititre system detected 129, underlining the accuracy of this sys-
tem for detecting colistin resistancewithahighCAof 97.8%.However,
the main disadvantage is that this system is not adapted to test only
one strain (at least eight strains need tobe testedper panel) (Table 1).
The performance of the MicroScan system for detection of coli-
stin resistance in Gram-negative bacilli was excellent regardless of
the nature of the resistance mechanism. Only a single colistin-
resistant A. baumannii isolate was not detected (Table 2), giving
the lowest VME rate of 0.8% (Table 3). The main inconvenience of
this panel was the narrow range of colistin concentrations tested,
the absence of a panel to test colistin only, and the high rate of
Table 3. Performances of the BMD panels
Sensititre UMIC
MicroScana
all the isolates
all isolates
excluding E. cloacae,
Salmonella, Acinetobacter
and Stenotrophomonas
isolatesa
VME rate Enterobacteriaceae 3.5% (4/114) Enterobacteriaceae 9.6% (11/114) Enterobacteriaceae 0% (0/114) 0% (0/105)
NFGNB 0% (0/19) NFGNB 21.1% (4/19) NFGNB 5.3% (1/19) 0% (0/3)
all species 3.0% (4/133) all species 11.3% (15/133) all species 0.8% (1/133) 0% (0/98)
ME rate Enterobacteriaceae 0% (0/32) Enterobacteriaceae 0% (0/32) Enterobacteriaceae 3.1% (1/32) 0% (0/23)
NFGNB 0% (0/20) NFGNB 0% (0/20) NFGNB 65.0% (13/20) 61.5% (8/13)
all species 0% (0/52) all species 0% (0/52) all species 26.9% (14/52) 22.2% (8/36)
CA rate Enterobacteriaceae 97.3% (142/146) Enterobacteriaceae 92.5% (135/146) Enterobacteriaceae 99.3% (145/146) 100% (128/128)
NFGNB 100% (39/39) NFGNB 89.7% (35/39) NFGNB 64.1% (25/39) 50% (8/16)
all species 97.8% (181/185) all species 91.9% (170/185) all species 91.9% (170/185) 94.4% (136/144)
NFGNB, non-fermenting Gram-negative bacteria.
aThe procedural manual of the MicroScan system indicates that results for E. cloacae, Salmonella and non-Enterobacteriaceae (except Pseudomonas)
should not be reported for colistin.
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false-resistance results found for non-fermenters (65%) (Table 3).
This ﬁnding supports a previous report showing a high rate of
false-resistance results in Acinetobacter species.4 The global rate
of MEs for the MicroScan system was thus 26.9%, whereas
Sensititre and UMIC systems did not give MEs (Table 3). However,
the procedural manual of the MicroScan panel indicates that
results for E. cloacae, Salmonella and non-fermenting Gram-nega-
tive bacilli except Pseudomonas spp. should not be reported, and
hence the MICs and categorization results are not provided for
those species. By excluding the results for those species, the ME
rate was lower (22.2% instead of 26.9%) (Table 3), but still not
acceptable (.3%) because of a high rate of false resistance found
for P. aeruginosa isolates (8/13). Therefore, non-susceptibility
results for non-fermenters including P. aeruginosa should be con-
ﬁrmed by the BMD referencemethod.
Conclusions
This study showed that variable results of colistin MICs can occur
depending on the BMD panels used. It revealed that the UMIC sys-
tem is not reliable for detection of colistin resistance, especially for
isolates with a low level of colistin resistance and for S. maltophilia
isolates. The performance of the MicroScan system was excellent,
but this system is not suited for testing the colistin susceptibility of
non-fermenters because of a high rate of false resistance. The
Sensititre system showed excellent concordance with the BMD
referencemethod andwas reliable for testing colistin susceptibility
for all the species of Gram-negative bacilli tested.
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